HJ Science Co., Ltd. (HKG:6132)

Market Cap	2.44B
Revenue (ttm)	16.30M +407.8%
Net Income	-179.65M
EPS	-2.98
Shares Out	73.60M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	97,000
Open	31.96
Previous Close	32.00
Day's Range	31.10 - 33.14
52-Week Range	25.88 - 82.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 27, 2026

About HJ Science

HJ Science Co., Ltd. engages in research and development of new small molecule drugs in the People’s Republic of China. It focuses on autoimmune, metabolic diseases, and oncology disorders. The company’s core product pipeline includes HJ787, a selective TYK2 inhibitor intended for the topical treatment of atopic dermatitis (AD), acne vulgaris (AV), neurodermatitis (ND), and psoriasis (PS), as well as oral treatment of AD, AV, ND, and PS in the autoimmune sector; HJ178, an orally available agent for type 2 diabetes, and potentially overweight or...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2017
• Employees: 113
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 6132

Financial Performance

Financial numbers in CNY

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 11, 2026

Data Sources Report a data error